CX Institutional Acquires New Holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

CX Institutional purchased a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 82,147 shares of the company's stock, valued at approximately $2,381,000. CX Institutional owned 0.17% of Amphastar Pharmaceuticals as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its holdings in Amphastar Pharmaceuticals by 222.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 715 shares of the company's stock valued at $26,000 after buying an additional 493 shares during the period. Parkside Financial Bank & Trust grew its position in Amphastar Pharmaceuticals by 806.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company's stock valued at $36,000 after acquiring an additional 871 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Amphastar Pharmaceuticals in the 4th quarter valued at $38,000. Tower Research Capital LLC TRC grew its position in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock valued at $43,000 after acquiring an additional 348 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock valued at $39,000 after acquiring an additional 424 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on AMPH shares. Piper Sandler cut their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Finally, Wells Fargo & Company cut their price objective on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday, May 8th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Amphastar Pharmaceuticals currently has an average rating of "Hold" and an average target price of $32.33.

Amphastar Pharmaceuticals Stock Down 2.3%

Shares of AMPH traded down $0.62 during midday trading on Friday, reaching $25.82. 402,402 shares of the stock were exchanged, compared to its average volume of 489,749. Amphastar Pharmaceuticals, Inc. has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The company's 50 day moving average is $24.67 and its two-hundred day moving average is $30.77. The company has a market capitalization of $1.22 billion, a P/E ratio of 8.61, a PEG ratio of 2.19 and a beta of 0.77.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.